"Today Fisher entered into a definitive agreement to acquire privately held Cellomics, Inc. for approximately $49 million in cash. Cellomics, with 2004 revenues of approximately $13 million, is a worldwide leader in the high-content-screening segment of the cellular-analysis market. The addition of Cellomics will build on Fisher's offering of drug-discovery solutions in the life-science marketplace, enabling researchers to accelerate the process of developing new medicines. In connection with this acquisition, Fisher and Carl Zeiss Jena GmbH, Cellomics' largest shareholder, agreed to closely collaborate in the high-content-screening field going forward."